6-methoxy-5-methyl-2-phenyl-1H-indole | 919090-41-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-methoxy-5-methyl-2-phenyl-1H-indole
• CAS: 919090-41-8
• 化学式: C₁₆H₁₅NO
• 分子量: 237.301
• InChiKey: WERILPCXWJQTSM-UHFFFAOYSA-N

物化性质

• 熔点：
  143-145 °C
• 沸点：
  432.1±40.0 °C(Predicted)
• 密度：
  1.143±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  25
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  6-methoxy-5-methyl-2-phenyl-1H-indole 在 三溴化硼 作用下， 以 二氯甲烷 为溶剂， 反应 1.33h， 生成 5-methyl-2-phenyl-1H-indol-6-ol
  参考文献：
  名称：

  INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF

  摘要：

  本发明的一种以通式(I)表示的化合物，具有EP1受体拮抗作用：[其中A代表苯环或类似物；Y代表C1-6烷基链或类似物；RN代表氢原子或C1-6烷基链；R1代表氢原子、C1-6烷基链或类似物；R2代表苯基，可能有取代基；可能有取代基的5元芳香杂环基，可能有取代基的6元芳香杂环基或类似物；R3代表卤原子、C1-6烷氧基或类似物；R4代表氢原子或类似物；R5代表氢原子或类似物]或其药学上可接受的盐。此外，本发明的化合物(I)可用作治疗或预防下尿路症状，特别是OAB的各种症状的药剂。

  公开号：

  US20120122931A1
• 作为产物：
  描述：

  alpha- 溴苯乙烯 、 2-chloro-5-methoxy-4-methylaniline 在 palladium diacetate 、 sodium t-butanolate 、 tri tert-butylphosphoniumtetrafluoroborate 作用下， 以 甲苯 为溶剂， 反应 3.0h， 以47.5%的产率得到6-methoxy-5-methyl-2-phenyl-1H-indole
  参考文献：
  名称：

  N-H Carbazole Synthesis from 2-Chloroanilines via Consecutive Amination and C−H Activation

  摘要：

  N-H carbazoles can be produced from 2-chloroanilines and aryl bromides via consecutive catalytic amination and C-H activation. In many instances, this can be done in a tandem manner in one pot. The methodologies developed can be used in the synthesis of a range of carbazoles, including the natural products Clausine P and glycozolidine and a precursor in the synthesis of Clausines H, K, O, and 7-methoxy-O-methylmukonal, and can be extended to the synthesis of indoles.

  DOI：

  10.1021/jo061749g

文献信息

• INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP2474530A1

  公开（公告）日：2012-07-11

  A compound represented by the general formula (I) of the present invention, which has an EP1 receptor antagonism: [wherein A represents a benzene ring or the like; Y represents a C1-6 alkylene group or the like; RN represents a hydrogen atom or a C1-6 alkyl group; R1 represents a hydrogen atom, a C1-6 alkyl group or the like; R2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic group which may have a substituent, a 6-membered aromatic heterocyclic group which may have a substituent or the like;R3 represents a halogen atom, a C1-6 alkoxy group or the like; R4 represents a hydrogen atom or the like; and R5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

  由本发明通式（I）代表的化合物，具有 EP1 受体拮抗作用： [其中 A 代表苯环或类似物；Y 代表 C1-6 亚烷基或类似物；RN 代表氢原子或 C1-6 烷基；R1 代表氢原子、C1-6 烷基或类似物；R2 代表可能具有取代基的苯基、可能具有取代基的 5 元芳香杂环基团、可能具有取代基的 6 元芳香杂环基团或类似基团；R3 代表卤素原子、C1-6 烷氧基或类似基团；R4 代表氢原子或类似基团；以及 R5 代表氢原子或类似基团]或其药学上可接受的盐。此外，本发明的化合物（I）可用作治疗或预防 LUTS，特别是 OABs 的各种症状的制剂。
• INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
  申请人：Kondo Tatsuhiro

  公开号：US20120122931A1

  公开（公告）日：2012-05-17

  A compound represented by the general formula (I) of the present invention, which has an EP 1 receptor antagonism: [wherein A represents a benzene ring or the like; Y represents a C 1-6 alkylene group or the like; R N represents a hydrogen atom or a C 1-6 alkyl group; R 1 represents a hydrogen atom, a C 1-6 alkyl group or the like; R 2 represents a phenyl group which may have a substituent, a 5-membered aromatic heterocyclic group which may have a substituent, a 6-membered aromatic heterocyclic group which may have a substituent or the like; R 3 represents a halogen atom, a C 1-6 alkoxy group or the like; R 4 represents a hydrogen atom or the like; and R 5 represents a hydrogen atom or the like] or a pharmaceutically acceptable salt thereof is provided. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

  本发明的一种以通式(I)表示的化合物，具有EP1受体拮抗作用：[其中A代表苯环或类似物；Y代表C1-6烷基链或类似物；RN代表氢原子或C1-6烷基链；R1代表氢原子、C1-6烷基链或类似物；R2代表苯基，可能有取代基；可能有取代基的5元芳香杂环基，可能有取代基的6元芳香杂环基或类似物；R3代表卤原子、C1-6烷氧基或类似物；R4代表氢原子或类似物；R5代表氢原子或类似物]或其药学上可接受的盐。此外，本发明的化合物(I)可用作治疗或预防下尿路症状，特别是OAB的各种症状的药剂。
• <i>N</i>-H Carbazole Synthesis from 2-Chloroanilines via Consecutive Amination and C−H Activation
  作者：Robin B. Bedford、Michael Betham

  DOI：10.1021/jo061749g

  日期：2006.12.1

  N-H carbazoles can be produced from 2-chloroanilines and aryl bromides via consecutive catalytic amination and C-H activation. In many instances, this can be done in a tandem manner in one pot. The methodologies developed can be used in the synthesis of a range of carbazoles, including the natural products Clausine P and glycozolidine and a precursor in the synthesis of Clausines H, K, O, and 7-methoxy-O-methylmukonal, and can be extended to the synthesis of indoles.